Showing results (151-160 of 286) with videos related to
Sort By:
Pageof 29
Cancer Immunity|October 21, 2010
Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trialsJedd D Wolchok, Jeffrey S Weber, Omid Hamid, et al.Cancer Immunology, Immunotherapy : CII|December 8, 2011
An immune-active tumor microenvironment favors clinical response to ipilimumabRui-Ru Ji, Scott D Chasalow, Lisu Wang, et al.Journal of Translational Medicine|April 18, 2020
The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019Paolo A Ascierto, Sanjiv S Agarwala, Alexander Eggermont, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2016
Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV MelanomaIgor Puzanov, Mohammed M Milhem, David Minor, et al.JAMA Surgery|September 1, 2021
Development and Validation of a Modified Pathologic Nodal Classification System for Cutaneous MelanomaAnthony T Nguyen, Michael Luu, Vina P Nguyen, et al.Journal of Drugs in Dermatology : JDD|September 4, 2024
Advances in Technology for Melanoma Diagnosis and Prognosis: An Expert Consensus PanelJoshua Burshtein, Danny Zakria, Milaan Shah, et al.British Journal of Cancer|March 22, 2017
Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapyAdi Nosrati, Katy K Tsai, Simone M Goldinger, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2014
Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancerRobert Dreicer, David MacLean, Ajit Suri, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 14, 2014
Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer typeZoran Gatalica, Carrie Snyder, Todd Maney, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanomaPatrick A Ott, Omid Hamid, Anna C Pavlick, et al.Pageof 29